Market Place
Sourcing Support
All News #Library
Biotech
Lilly Completes Acquisition of Verve Therapeutics
25 Jul 2025 //
PR NEWSWIRE
Eli Lilly nears $1.3 Billion Deal for Verve Therapeutics
17 Jun 2025 //
REUTERS
Verve Posts Clean Pcsk9 Editor Profile, Teeing Up Lilly Decision
14 Apr 2025 //
FIERCE BIOTECH
Vertex axes Verve gene editing pact amid shift in R&D priorities
28 Feb 2025 //
FIERCE BIOTECH
Verve Therapeutics First Patient Dosed In VERVE-102 Heart-2 Phase 1b Trial
07 May 2024 //
PRESS RELEASE
Verve Halts Trial for Lead Gene Editing Program Due to Safety Concerns
03 Apr 2024 //
BIOSPACE
Beam offloads Verve rights to Lilly for up to $600M
31 Oct 2023 //
FIERCE BIOTECH
Lilly beams up Verve gene therapy programs for $600M from deal-hungry Beam
31 Oct 2023 //
PRESS RELEASE
Verve to Present Data from the heart-1 Phase 1b Clinical Trial of VERVE-101
26 Sep 2023 //
PRESS RELEASE
Verve to Participate in the 2023 Cantor Global Healthcare Conference
21 Sep 2023 //
PRESS RELEASE
Verve Appointed Frederick T. Fiedorek, M.D., as Chief Medical Officer
18 Sep 2023 //
PRESS RELEASE
Intellia, Verve run trials abroad amid FDA’s ‘cautious’ approach to gene editing
17 Aug 2023 //
ENDPTS
Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
03 Aug 2023 //
PRESS RELEASE
Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing
16 Jun 2023 //
ENDPTS
Verve Establishes Collaboration with Lilly to Advance In Vivo Gene Editing Program
15 Jun 2023 //
PRESS RELEASE
Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
01 Jun 2023 //
PRESS RELEASE
Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes
23 May 2023 //
PRESS RELEASE
VERVE-101 Awarded Passport for Heterozygous Familial Hypercholesterolemia
14 Feb 2023 //
PRESS RELEASE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.